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Purpose: Tumour volumetric changes can be observed during 
radical chemo-radiotherapy (CRT) for locally advanced non-small 
cell lung cancer (NSCLC); but it is unclear whether these changes 
are predictive of outcomes. This study aims to a) examine 
whether the magnitude of tumour regression is correlated with 
disease control and survival; b) explore the potential difference 
between adenocarcinoma (AC) and non-adenocarcinoma (non-
AC) NSCLC subtypes.  
Methods and Materials: Primary tumour volumes were recorded 
and analyzed on weekly serial cone beam computed tomography 
(CBCT) images of NSCLC patients treated with CRT from January 
2006 to June 2007 at our institution1. Tumour volume regression 
was divided into three categories: < 10%, 10-30%, and ≥ 30%. 
Outcome measures included locoregional failure-free survival 
(LRFFS), distant failure-free survival (DFFS), and overall survival 
(OS), which were calculated using the Kaplan-Meier method. 
Univariate analysis (UVA) and multivariate analysis (MVA) of 
LRFFS, DFFS and OS were performed using the Cox regression 
model. Further analysis was performed comparing AC and non-
AC subgroups. 
Results: Forty-five patients with Stage II-III NSCLC were 
included. Median age was 64 years (range: 43 – 79 years). Median 
follow up was 22.1 months for all patients, and 90 months for 
alive patients (range: 0.9-108 months). The distribution of 7th 
Ed. AJCC stage was as follows: Stage IIB (T3N0) 8.9%; IIIA 66.7%; 
IIIB 24.4%. Twenty patients (44.4%) had AC, while 25 patients 
(55.6%) had non-AC histologies. All patients received concurrent 
chemotherapy. Twenty-eight patients (62.3%) received a total 
radiation dose of ≥ 60 Gy, 15 patients (33.3%) received 45 Gy as 
part of trimodality therapy determined upfront, and two patients 
(4.4%) received 58-59 Gy due to missed fractions. Among all 45 
patients, 23 patients (51.1%) had ≥ 30% regression by fraction 15 
and 32 patients (71.1%) by treatment completion. In UVA for all 
patients, young age (p = 0.02) and AC histology (p = 0.03) were 
significantly associated with better LRFFS; young age was 
significantly associated with better DFFS (p = 0.048) and OS (p = 
0.04). For patients with AC histology, MVA showed that ≥ 30% 
regression by fraction 15 and younger age were significantly 
associated with better LRFFS (p = 0.007, 0.006 respectively), 
DFFS (p = 0.007, 0.004), and OS (p = 0.02, 0.004). For patients 
with non-AC histology, ≥30% regression by treatment completion 
was significantly associated with better LRFFS (p = 0.02), but 
none of the factors had any significant correlation with DFFS or 
OS.  
Conclusions: Evaluation of primary tumour regression on CBCT 
images during CRT may be predictive of treatment response. 
Early tumour regression, as indicated by ≥30% regression by 
fraction 15, was shown to be associated with better outcomes 
for adenocarcinoma histologic subtype in our study. This 
observation may provide insight into when, how and in which 
patients to best utilize adaptive radiotherapy.  
1. J Thorac Oncol. 2011; 6: 531-6. 
 
163 
CUMULATIVE INCIDENCE OF BRAIN METASTASIS AFTER DIAGNOSIS 
OF NON-SMALL CELL LUNG CANCER: ESTIMATES FROM A 
REGIONAL CANCER CENTRE COHORT  
Adrijana D'Silva1, Shannon Otsuka1, Haocheng Li1, Jackson Wu2, 
Don Morris1, Gwyn Bebb1 
1Tom Baker Cancer Centre, Calgary, AB 
2University of Calgary, Calgary, AB 
 
Purpose: Non-small cell lung cancer (NSCLC) is the most common 
primary cancer to metastasize to the brain. However, the 
incidence or likelihood of developing brain metastasis, after 
initial diagnosis and treatment, is generally unknown, as 
provincial population-based cancer registries do not routinely 
capture metastatic relapses. At our centre, a retrospective 
cohort study has gathered longitudinal clinical data for all NSCLC 
patients consulted since 1999 (Glans-Look Lung Cancer 
Database). In this report, we describe the cumulative incidence 
of brain metastasis observed for NSCLC patients diagnosed 
between 1999 and 2010. 
Methods and Materials: Clinical data, including date of brain 
metastasis diagnosed by CT/MR imaging, is abstracted from 
electronic and paper charts by full time research coordinators. 
De novo cases of brain metastasis were defined as positive CT/MR 
within 30 days of initial cancer diagnosis and distinguished from 
relapsing cases (Stages I-IV at initial diagnosis). Cumulative 
incidence of relapsing brain metastasis was computed, stratified 
by cancer stage at initial diagnosis and adjusted for competing 
risk of death before developing brain metastasis. Survival 
difference between de novo and relapsing brain metastasis 
(those initially Stage I-III) was examined by pre-specified 
proportional hazard regression model, adjusting for age and year 
of diagnosis.  
Results: A total of 5,264 NSCLC incident cases diagnosed 
between 1999 and 2010 were identified and analyzed (90% have 
died). Median age at initial cancer diagnosis was 70 years. 
Proportion of Stage I, II, III and IV patients was 18%, 8.3%, 20% 
and 54% respectively. A total of 451 patients relapsed with brain 
metastasis, giving a five-year cumulative incidence of 8.6%, 14% 
and 8.0% for Stage I-II, Stage III, and Stage IV, respectively. 
Among the 2,827 Stage IV patients, 631 (22%) and 179 (6.3%) had 
de novo and relapsing brain metastasis, respectively. Median 
survival of de novo brain metastasis (n = 631, 3.2 months, CL 2.8-
3.5 months) was worse than that for Stage I-III relapsing cases (n 
= 272, 3.9 months, CL 3.3-4.7 months), adjusted HR 1.24, CL 
1.07-1.44 months. 
Conclusions: The five-year cumulative incidence of brain 
metastasis was 8.6%, 13%, and 8.0% among Stage I-II, Stage III 
and Stage IV NSCLC patients. Twenty-two percent of Stage IV 
NSCLC patients presented with de novo brain metastasis, whose 
median survival was significantly worse than that for Stage I-III 
patients with relapsing brain metastasis. 
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Purpose: Kaposi sarcoma (KS) is a non-curable malignancy which 
can present with cutaneous lesions. Some patients with KS can 
have a long indolent chronic course. Radiotherapy is often used 
to help palliate local symptoms for cutaneous lesions which bleed 
or cause pain. 
Methods and Materials: A retrospective review was undertaken 
for all KS patients treated with radiotherapy at our centre from 
January 2, 1999 to December 31, 2014 (inclusive). This study was 
approved by the local hospital Research Ethics Board. 
Demographic information (date of birth, gender, co-morbidities) 
were retrieved along with radiotherapy details, symptoms, 
treatment side-effects and outcomes. 
Results:  A total of 48 patients with KS (44 classical, 0 endemic, 
one iatrogenic, three AIDS related) were seen in our 
multidisciplinary skin clinic during this study period. Eighteen 
patients received radiotherapy to 107 sites (1-20 sites per 
patient). There were five females and 13 males. Ages at the time 
of initial radiotherapy ranged from 44-93 years of age. 
Radiotherapy dose ranged from 6 Gy in 1 fraction to 30 Gy in 10 
fractions with the most common scheme being 8 Gy in 1 fraction 
or 20 Gy in 5 fractions. Of the 107 sites treated, 106 showed 
regression of the KS lesions with benefit in terms of pain, 
swelling or bleeding. One site in the posterior leg showed 
progressive KS despite 8 Gy in 1 fraction which continued to 
bleed and ulcerate. Two patients had initial partial response to 
radiotherapy but had relapse within the radiated fields requiring 
repeat radiotherapy. One patient had relapse within the radiated 
fields and subsequently was observed. No fatal toxicities 
occurred. The most common side effects were dry 
desquamation, hyperpigmentation and lymphedema of the legs. 
